Feeding Tolerance and Growth of Preterm Infants Consuming a Supplement Containing Two Human Milk Oligosaccharides (HMOs)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-14
SponsorSociété des Produits Nestlé (SPN)

About this trial

The goal of this post-market study is to describe the effect of a liquid supplement containing 2 specific human milk oligosaccharides (HMOs), 2'-fucosyllactose \[2'FL\] and lacto-N-neotetraose \[LNnT\], on feeding tolerance, growth, and adverse events of special interest in preterm infants in a real-world setting.

A comparison with data collected retrospectively from a historical group at each site will be made for time to reach full enteral feeding, growth and adverse events. Infants in the historical group were not exposed to an HMO supplement but followed the same local nutrition protocol to avoid confounding by differences in clinical or feeding practice.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Written informed consent has been obtained from at least one parent (or other legally acceptable representative [LAR], if applicable)

Infant's parent(s)/LAR is of legal age of majority, has parental authority, must understand the consent form and other relevant study documents, and is willing and able to fulfil the requirements of the study protocol

Infant gestational age is ≤ 34 weeks as determined by the first day of the mother's last menstrual period or by fetal ultrasound

Infant birth weight ≤ 2500g

Disqualifiers

Infant has hemodynamic instability as evidenced by clinical signs of sepsis, hypotension (MAP < 5th percentile for age for at least three hours), or is receiving vasopressor drugs

Infant has received an exchange transfusion within the past 48 hours

Infant has had an episode of severe asphyxia at birth (PH less than 7.0)

Infant has signs of necrotizing enterocolitis according to modified Bell staging criteria (stage IIA or higher)

Trial design

Design model

Single group

Treatments tested in this trial

  • HMO supplement

    Dietary supplement

    Liquid supplement containing 2 specific HMOs. Supplement will be given 3-4 times a day, not mixed with any feeding.

Treatment groups

188 Participants
are divided into 1 treatment group
Group A: HMO supplementOther 1 intervention

Trial outcomes

Primary outcomes

1

Feeding tolerance

Time to reach full enteral feeding rate of 150 mL/kg/day

Time frame
From birth until achievement of full enteral feeding (1 to 3 weeks)
2

Feeding tolerance

Time to reach cessation of parenteral feeding

Time frame
From birth until achievement of full enteral feeding (1 to 3 weeks)

Secondary outcomes

1

Gastrointestinal tolerance

Through data collected from neonatal unit records

Time frame
From enrollment (baseline) until NICU discharge (V5), assessed up to 13 weeks
2

Weight gain

Measured in kilograms per day

Time frame
From enrollment (baseline) until NICU discharge (V5), assessed up to 13 weeks
3

Length gain

Measured in centimeters per week

Time frame
From enrollment (baseline) until NICU discharge (V5), assessed up to 13 weeks
4

Head circumference gain

Measured in centimeters per week

Time frame
From enrollment (baseline) until NICU discharge (V5), assessed up to 13 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.